Please click
 User   Pwd      Remember
Article Search: 
BiotechEast
· Home
· About us
· Services
· FAQ
· Contact us
Info Resources
· Companies
· Institutes
· Science parks
· Life science news
· Company spotlight
· Taiwan bio report
· Feature articles
· Asia-Pacific events
· Investment corner
· Technology transfer
· Int'l biotech links
· Info resources search
· Job listings
· Log out
Partners
Previous  8 9 10 11 12 13 14 15 16 17 ... Total pages:251  Next 

Life Science News

(China) Ascletis secures China market rights from Janssen for TMC310911, a next-generation HIV protease inhibitor


(BiotechEast staff)

30 April, 2013
China and US-based drug development firm Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland for TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in Greater China, including mainland China and Macau. Janssen will retain all rights in the rest of the world and is eligible to receive royalties based on product sales in Greater China.




Life Science News

(Taiwan) Ma lauds pharmaceutical care program


(Taiwan Today)

29 April, 2013
ROC President Ma Ying-jeou said April 27 that the pharmaceutical care program Taiwan instituted in 2010 has saved more than NT$50 million (US$1.69 million) in medical expenses.
More...




Life Science News

(Taiwan) Medical device sector should look to Israel for inspiration and cooperation: Forum speakers


(BiotechEast staff)

1 May, 2013
Israel and Taiwan are both small-sized technology-focused export-oriented countries, and share a number of traits that bode well for increased cooperation in each other's medical device industries. This was one of several take-home messages from an industry forum held by the Israel Economic and Cultural Office in Taipei on Tuesday. The event was held primarily to promote and encourage medical device industry notables form Taiwan to attend the 2nd 'Med in Israel' international conference being held June 10-13 in Tel Aviv.




Life Science News

(Taiwan) Taiwan's biotech sector seen as ripe for growth


(China Post)

28 April, 2013
Taiwan's biotechnology will continue to expand, in terms of both investment and business turnover, as the global market grows, the Ministry of Economic Affairs said yesterday.
More...




Life Science News

(Taiwan) Seminar on Israeli medical devices industry to be held


(China Post, Taiwan)

29 April, 2013
Israel's representative office in Taiwan will hold a seminar Tuesday to promote the Israeli medical devices industry and invite Taiwanese companies in related fields to attend an international show on medical innovation in Israel in June.
More...




Life Science News

(Taiwan) Containment begins as H7N9 spreads to Taiwan


(China Post, Taiwan)

25 April, 2013
Taiwan has its first confirmed case of H7N9 avian influenza, the Central Epidemic Command Center (CECC) announced yesterday.
More...




Life Science News

(Taiwan) Work on H7N9 virus still in R&D stage: health official


(Focus Taiwan)

24 April, 2013
The Department of Health (DOH ) said Wednesday that work on the new H7N9 avian flu virus strain obtained from China is still in the research and development stage and that the DOH has invited local experts to discuss ways of combating the deadly flu.
More...




Life Science News

(Taiwan) Bird Flu Strain Spreads as Taiwan Reports First H7N9 Infection


(BusinessWeek)

24 April, 2013
Taiwan confirmed an H7N9 bird flu infection in a traveler returning to the island from China, the first incidence of the killer virus spreading outside the mainland.
More...




Life Science News

(Taiwan) FDA unveils pharmaceutical regulatory easing


(Taiwan Today)

23 April, 2013
Approvals for new drugs imported into Taiwan will be fast-tracked under a streamlined procedure announced April 22 by the ROC Food and Drug Administration.
More...




Life Science News

(Taiwan) Advaxis and FusionVax sign MoU for the license of Advaxis' ADXS-HPV in Asia


(BiotechEast staff)

22 April, 2013
Advaxis, Inc., (OTCBB: ADXS), a developer of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc., under which Advaxis intends to exclusively license its lead clinical stage product candidate, ADXS-HPV, to Taiwan-based FusionVax for Asian markets.




Sponsors

Events



Taiwan Life Sciences Bulletin

Enter email address to receive free e-newsletter


Sample

Disclaimer and Privacy Policy